Department of Error

can stop taking primaquine at the first signs of clinically significant haemolysis.However, even with these interventions, adverse events will inevitably occur and this risk will vary considerably with the local context.The increased uptake of safe and effective radical cure, either with primaquine or tafenoquine, will require an integrated package of interventions, patient education, and community engagement.Ultimately, the public health benefit of the 7 day regimen will rest on minimising the risk of serious adverse events and weighing this risk against the considerable (and usually underestimated) benefits in preventing recurrent P vivax infection and its associated morbidity and mortality.We declare no competing interests.